U009 In Office Surgical Techniques for the Treatment of Moderate to Severe Hidradenitis Suppurativa (HS)
DESCRIPTION
Hidradenitis Suppurativa (HS) is a devastating chronic condition with the lowest quality of life of any skin condition that disproportionately affects women and patients of low socio-economic status. Despite the recent expansion of biologic therapies, patients with moderate and severe HS with established sinus tracts and tunnels, need surgical intervention to manage their disease. This focus session will review and discuss the different in-office surgical treatments using liquid nitrogen, hair removal lasers, surgical instruments and Co2 lasers that should be a part of a dermatologist’s surgical skill set. We also plan to discuss post-op care and most common complications.
LEARNING OBJECTIVES
Identify patients who are the most appropriate candidates for different types of in-office surgical treatments in patients suffering from moderate to severe Hidradenitis Suppurativa.
Describe and demonstrate the latest techniques, results (including recurrence rates) and post-op care for patients undergoing in-office surgical treatments of patients suffering from moderate to severe Hidradenitis Suppurativa.
Discuss the most common side effects of the procedures and how to prevent them in our busy daily practice.
SCHEDULE
7:30 AM
In Office Surgical Techniques for the Treatment of Moderate to Severe Hidradenitis Suppurativa (HS)
DIRECTOR
Akhil Wadhera, MD, FAAD
SPEAKERS
Steven Daniel Daveluy, MD, FAAD
Iltefat H. Hamzavi, MD, FAAD
Christopher John Sayed, MD, FAAD
DISCLOSURES
Steven Daniel Daveluy, MD, FAAD
AbbVie – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Incyte – Advisory Board(Honoraria); Insmed – Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Investigator(Grants/Research Funding); Novartis – Speaker(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding); Sanofi – Investigator(Grants/Research Funding); UCB – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Honoraria);
Iltefat H. Hamzavi, MD, FAAD
AbbVie – Advisory Board(Fees); Almirall – Consultant (1099 relationship)(Fees); Avita – Investigator(Grants/Research Funding); Beiersdorf, Inc. – Advisory Board(Fees); Boehringer Ingelheim – Consultant(Fees); Clinuvel – Investigator(Fees); Galderma Laboratories, L.P. – Investigator(Fees); Global Vitiligo Foundation – Board of Directors(No Compensation Received); Hidradenitis Suppurativa Foundation – Board of Directors(No Compensation Received); Incyte Corporation – Investigator(Grants/Research Funding); Janssen Biotech – Investigator(Grants/Research Funding); L'Oreal USA Inc. – Investigator(Grants/Research Funding); Lenicura – Investigator(Equipment); Merck – Investigator(Grants/Research Funding); MyDerm Portal, Inc – Stockholder(Stock); Novartis – Consultant(Fees); Pfizer Inc. – Investigator(Fees); Sonoma Biotherapeutics – Investigator(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – Investigator(Grants/Research Funding); Teva Pharmaceutical Industries Ltd. – Investigator(Fees); UCB – Consultant(Fees); Union Therapeutics – Consultant(Fees); Vimela – Consultant (1099 relationship)(Fees);
Christopher John Sayed, MD, FAAD
AbbVie – Advisory Board(Fees), Investigator(Fees), Speaker(Fees); Alumis – Consultant(Fees); AstraZeneca – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); ChemoCentryx – Investigator(Grants/Research Funding); Elasmogen – Consultant (1099 relationship)(Fees); Eli Lilly – Stockholder Public Company(Stock); Incyte – Consultant (1099 relationship)(Fees); Incyte Corporation – Investigator(Grants/Research Funding); InflaRx – Consultant(Fees), Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Investigator(Fees), Speaker(Honoraria); Sandoz Pharmaceuticals AG – Consultant (1099 relationship)(Honoraria); Sanofi – Consultant (1099 relationship)(Fees); UCB – Advisory Board(Honoraria), Consultant(Fees), Investigator(Grants/Research Funding);
Akhil Wadhera, MD, FAAD
No financial relationships exist with ineligible companies.